ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Center for Breakthrough Medicines (CBM), a cell and gene therapy contract services firm, plans to expand research and manufacturing with an investment from SK. CBM was established in 2019 by the Discovery Labs after the latter acquired a GlaxoSmithKline R&D center in King of Prussia, Pennsylvania. CBM says it will hire 2,000 people over the next 4 years. SK, a South Korean company with investments in life sciences, energy, and other industries, says it will partner with CBM in providing cell and gene therapy services.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X